Abstract
Background: Colorectal cancer (CRC) ranks as the third most common cancer and the third most killing cancer worldwide [1]. The addition of oxaliplatin to fluorouracil (FOLFOX) or capecitabine (CAPOX) has become a fundamental component of chemotherapeutic regimens and chemoradiation in adjuvant treatment of CRC cancer. Excision repair cross-complementation group 1 (ERCC1) encodes an enzyme that is essential for the efficient repair of DNA damage induced by platinum compounds including Oxaliplatin. Purpose: This study aims to investigate the role of ERCC1 as a predictive and prognostic marker in colorectal patients receiving oxaliplatin based chemotherapy and chemoradiation. Patients and Methods: 100 annotated stage III CRC patients were prepared as immunohistochemical (IHC) analysis of ERCC1 protein expression. All of the patients received oxaliplatin based chemotherapy. Results: Analysis of data showed that high ERCC1 expression was significantly associated with early treatment failure and disease free survival among patient with stage III CRC. Conclusion: High ERCC1 expression was an independent predictor factor of early treatment failure (P = 0.004).
Highlights
Colorectal cancer (CRC) ranks as the third most common cancer and the third most killing cancer worldwide [1]
2) Excision repair cross-complementation group 1 (ERCC1) protein expression: ERCC1 high expression was observed in 21 cases (21%) while 79 cases (79%) showed low ERCC1 expression
ERCC1 expression was significantly correlated with high histologic grade (p = 0.003)
Summary
Colorectal cancer (CRC) ranks as the third most common cancer and the third most killing cancer worldwide [1]. Some authors believed that the increased removal of bulky DNA adducts, which can be produced by the other detrimental carcinogenic factors, is beneficial for the genome stability and cancer prevention [9] These adducts are recognized and repaired by the nucleotide excision repair (NER) pathway. According to the previous clinical data, this study aims to investigate the prognostic and predictive role of ERCC1 expression among patients with stage III CRC receiving oxaliplatin based chemotherapy. Purpose: This study aims to investigate the role of ERCC1 as a predictive and prognostic marker in colorectal patients receiving oxaliplatin based chemotherapy and chemoradiation. Results: Analysis of data showed that high ERCC1 expression was significantly associated with early treatment failure and disease free survival among patient with stage III CRC.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
